curacleltd (A365270) Stock Overview
A bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A365270 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
curacle co.,ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩13,970.00 |
| 52 Week High | ₩14,400.00 |
| 52 Week Low | ₩3,600.00 |
| Beta | 2.17 |
| 1 Month Change | 67.91% |
| 3 Month Change | 182.22% |
| 1 Year Change | 119.31% |
| 3 Year Change | 15.74% |
| 5 Year Change | n/a |
| Change since IPO | -54.42% |
Recent News & Updates
Is curacleltd (KOSDAQ:365270) A Risky Investment?
Dec 19
Is curacleltd (KOSDAQ:365270) A Risky Investment?
Aug 29Recent updates
Is curacleltd (KOSDAQ:365270) A Risky Investment?
Dec 19Is curacleltd (KOSDAQ:365270) A Risky Investment?
Aug 29Is curacleltd (KOSDAQ:365270) Using Debt Sensibly?
Feb 19Is curacleltd (KOSDAQ:365270) Using Too Much Debt?
Nov 01curacleltd (KOSDAQ:365270) Has Debt But No Earnings; Should You Worry?
Jun 26Is Curacle (KOSDAQ:365270) Using Too Much Debt?
Feb 27Shareholder Returns
| A365270 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 15.4% | 5.7% | 7.6% |
| 1Y | 119.3% | 44.7% | 103.7% |
Return vs Industry: A365270 exceeded the KR Biotechs industry which returned 48.8% over the past year.
Return vs Market: A365270 exceeded the KR Market which returned 105.2% over the past year.
Price Volatility
| A365270 volatility | |
|---|---|
| A365270 Average Weekly Movement | 14.7% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in KR Market | 13.1% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A365270's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A365270's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Jaehyeon Yoo | curacle.com |
curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company’s products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- ß/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combining Tie2 agonist and anti-VEGF functions for the treatment of wAMD. It also develops MT-105 for the treatment of irritable bowel diseases; MT-201, a non-bleeding anti-thrombotic antibody targeting PD-X; MT-202, a dual-mechanism therapy combining PD-X inhibition and Tie2 agonism for the treatment of acute ischemic stroke and heart failure with preserved ejection fraction; CU71, a next-generation neurovascular stabilizer for the treatment of alzheimer's disease; and CP01-R01, a first oral endothelial stabilizer–based candidate for companion animal CKD therapy.
curacle co.,ltd. Fundamentals Summary
| A365270 fundamental statistics | |
|---|---|
| Market cap | ₩295.56b |
| Earnings (TTM) | -₩17.50b |
| Revenue (TTM) | ₩1.14b |
Is A365270 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A365270 income statement (TTM) | |
|---|---|
| Revenue | ₩1.14b |
| Cost of Revenue | ₩14.25m |
| Gross Profit | ₩1.13b |
| Other Expenses | ₩18.62b |
| Earnings | -₩17.50b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -827.08 |
| Gross Margin | 98.75% |
| Net Profit Margin | -1,535.23% |
| Debt/Equity Ratio | 33.7% |
How did A365270 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/13 07:53 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
curacle co.,ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.